A woman holds a small bottle labelled with a “Coronavirus COVID-19 Vaccine” sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic Indias Biological E. stated on Tuesday it has participated in a licensing agreement with Providence Therapeutics Holdings to produce the Canadian companys mRNA COVID-19 vaccine in India.Biological E., which also has a different offer to produce about 600 million dosages of Johnson & & Johnsons (JNJ.N) COVID-19 shot annually, will run a clinical trial of Providences vaccine in India and seek emergency use approval for it, the company stated in a statement.Providence will offer up to 30 million doses of its mRNA vaccine, PTX-COVID19-B, to Biological E., and will likewise offer the needed innovation transfer of the shot, with a minimum production capacity of 600 million dosages in 2022 and a target capacity of 1 billion doses.Financial details of the transaction were not disclosed.India has actually been dealing with a disastrous 2nd wave of the pandemic and has handled to totally immunize only about 3% of its population. On Monday, the Serum Institute of India stated it will increase production of AstraZenecas (AZN.L) shot by almost 40% in June, a step towards bridging the shortage in the country. learn more “The mRNA platform has actually become the front runner in delivering the very first vaccines for emergency situation use to combat the COVID-19 pandemic,” said Mahima Datla, Biological E.s managing director.Messenger ribonucleic acid (mRNA) vaccines trigger the body to make a protein that is part of the virus, setting off an immune action. U.S. companies Pfizer (PFE.N) and Moderna (MRNA.O) usage mRNA technology in their COVID-19 shots.Indias drug regulator has authorized medical trials of another mRNA vaccine established by local firm Gennova Biopharmaceuticals, and the federal government has stated it will money the studies.Our Standards: The Thomson Reuters Trust Principles.